CSIMarket
 
Emergent Biosolutions Inc   (EBS)
Other Ticker:  
 
 
Price: $2.4700 $0.02 0.816%
Day's High: $2.52 Week Perf: 6.01 %
Day's Low: $ 2.37 30 Day Perf: 45.29 %
Volume (M): 1,505 52 Wk High: $ 13.67
Volume (M$): $ 3,718 52 Wk Avg: $5.09
Open: $2.50 52 Wk Low: $1.42



 Market Capitalization (Millions $) 126
 Shares Outstanding (Millions) 51
 Employees 2,100
 Revenues (TTM) (Millions $) 1,049
 Net Income (TTM) (Millions $) -761
 Cash Flow (TTM) (Millions $) -531
 Capital Exp. (TTM) (Millions $) 52

Emergent Biosolutions Inc
Emergent BioSolutions Inc. is a publicly traded biotechnology company headquartered in Gaithersburg, Maryland, USA. The company specializes in the development, manufacturing, and commercialization of vaccines and immunotherapies for infectious diseases and biodefense.

Founded in 1998, Emergent BioSolutions has grown to become a leading provider of medical countermeasures to governments, militaries, and private organizations around the world. The company's portfolio of products includes vaccines for anthrax, smallpox, and typhoid fever, as well as treatments for botulism and nerve agents.

Emergent BioSolutions operates a state-of-the-art manufacturing facility in Baltimore, Maryland, which has the capacity to produce millions of vaccine doses per year. The facility is equipped with advanced technologies and processes to ensure the highest levels of quality and safety.

The company has a strong focus on research and development, with dedicated teams working on the discovery and development of new vaccines and therapies. Emergent BioSolutions also partners with leading academic and research institutions to accelerate the development of breakthrough treatments.

In addition to its biodefense work, Emergent BioSolutions is actively involved in developing treatments for infectious diseases such as COVID-19. The company has partnered with other biotech firms and government agencies to develop potential treatments and vaccines for the virus.

Overall, Emergent BioSolutions Inc. is a dynamic and innovative biotech company that is dedicated to improving public health and safety through the development and manufacturing of life-saving vaccines and therapies.


   Company Address: 300 Professional Drive Gaithersburg, 20879 MD
   Company Phone Number: 631-3200   Stock Exchange / Ticker: NYSE EBS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Emergent Biosolutions Inc

Strategic Contract Win Boosts Emergent Biosolutions Inc Stock Price and Future Growth Opportunities

Emergent Biosolutions Inc has experienced a significant increase in its stock price over the past few trading days, which can be attributed to some positive news for the company. The Maryland-based life sciences company recently announced that it has been awarded a lucrative contract by the U.S. Department of Defense to supply its BioThrax Anthrax Vaccine Adsorbed to all branches of the military. This contract has a maximum value of $235.8 million and will run for at least five years, with the option to extend for an additional five years.
This contract is a major win for Emergent Biosolutions Inc, as BioThrax is the only anthrax vaccine licensed by the FDA for both pre-exposure and post-exposure prophylaxis against anthrax disease. The company has a long-standing partnership with the DoD and has been supplying BioThrax to military personnel for over a decade. With this new contract, Emergent Biosolutions Inc is poised to continue serving as a reliable supplier of this critical medical countermeasure to protect the U.S. military from the threat of anthrax.

Contract

Emergent BioSolutions Bags $235.8 Million Contract to Supply Anthrax Vaccine to U.S. Military

Published Thu, Jan 11 2024 1:01 PM UTC

Emergent BioSolutions Inc, a Maryland-based life sciences company, announced it has been awarded an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract, which has a maximum value of $235.8 million. The contract requires the company to supply its BioThrax Anthrax Vaccine Adsorbed to all branches of the U.S. military. BioThrax is the only anthrax vaccine licen...

Emergent Biosolutions Inc

Emergent BioSolutions Reports Surge in Revenue for Q3 2023, Despite Continuing Profitability Challenges

Emergent BioSolutions Inc. (EBS), a leading company in the Major Pharmaceutical Preparations industry, has reported some interesting financial results for the third quarter of 2023. While many of its industry counterparts have experienced declines in revenue, EBS has shown a significant surge in revenue, increasing by 12.708% from the previous year to $270.50 million.
However, it is worth noting that despite the revenue increase, EBS has also seen an extension of losses, with a shortfall of $-5.08 per share. This is an improvement from the previous year when the company reported a loss of $-5.15 per share. For the fiscal interval ending September 30, 2023, EBS realized a net shortfall of $-263.400 million, which is higher than the $-75.700 million from the same period last year.

Product Service News

Emergent BioSolutions Secures $75 Million Contract Option and Achieves Steady Revenue Growth

Published Tue, Nov 28 2023 11:59 AM UTC



In a significant boost to Emergent BioSolutions Inc. (NYSE: EBS), the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract option worth $75 million. This contract aims to procure doses of CYFENDUS, the newly licensed anthrax vaccine for the United States Department of Health and Human Services. The company expects to com...

Emergent Biosolutions Inc

Emergent Biosolutions Inc. Dominates Major Pharmaceutical Preparations Industry with Skyrocketing Revenue Amidst Share Shortfall and Stock Decline

Financial News Report: Emergent Biosolutions Inc. Reports Increase in Revenue, Share Shortfall, and Declining Stock Performance
Emergent Biosolutions Inc. recently released its financial results for the most recent fiscal period, revealing a significant increase in revenue. However, the company also reported a shortfall per share. This news comes amid overall growth in the major pharmaceutical preparations industry during the second quarter of 2023.
According to the report, Emergent Biosolutions Inc. experienced a surge in revenue, reaching $337.90 million, representing a 39.225% increase from the same reporting period the previous year. This growth is higher compared to other major pharmaceutical preparations industry contemporaries, which only saw a 2.65% rise in business during the second quarter of 2023 when compared to Q2 of 2022.






 

Emergent Biosolutions Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Emergent Biosolutions Inc does not provide revenue guidance.

Earnings Outlook
Emergent Biosolutions Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com